Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
Mahaffey KW, Tuttle KR, Arici M, et al.
Eur Heart J. Pub. online 30 Aug 2024.
Leggi
Breaking news
FDA Clears First Device to Enable Automated Insulin Dosing for Individuals with Type 2 Diabetes
26/08/2024
Leggi
AIFA: È possibile utilizzare, in regime di rimborsabilità SSN, il medicinale JARDIANCE (Empagliflozin) per la seguente indicazione terapeutica: Jardiance è indicato negli adulti per il trattamento della malattia renale cronica
13/08/2024
Leggi
AIFA: Aggiornato il Piano Terapeutico web based di Jardiance (Empagliflozin) per la seguente indicazione terapeutica: insufficienza cardiaca cronica sintomatica, con l’eliminazione del blocco relativo al valore della Frazione di Eiezione Ventricolare (FEVS %) se ≥ 60%
13/08/2024
Leggi
Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes
Astbury NM
Diabetes Obes Metab. Pub. online 19 Aug 2024.
Leggi
Machine learning-based reproducible prediction of type 2 diabetes subtypes
Tanabe H, Sato M, Miyake A, et al.
Diabetologia. Pub. online 21 Aug 2024.
Leggi
Sweetened beverages and atrial fibrillation in people with prediabetes or diabetes
Gan X, Ye Z, Zhang Y, et al.
Diabetes Obes Metab. Pub. online 19 Aug 2024.
Leggi
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care
Fadini GP, Longato E, Morieri ML, et al.
Diabetologia. Pub. online 23 Aug 2024.
Leggi
Sodium-glucose cotransporter-2 inhibitors, dulaglutide, and risk for dementia: a population-based cohort study
Hong B, Bea S, Ko HY, et al.
Ann Intern Med. Pub. online 27 Aug 2024.
Leggi
Real-world evidence of off-label use of commercially automated insulin delivery systems compared to multiple daily insulin injections in pregnancies complicated by type 1 diabetes
Quirós C, Herrera Arranz MT, Amigó J, et al.
Diabetes Technol Ther. Pub. Online 26 Aug 2024.
Leggi